Los Angeles, CA -- (SBWIRE) -- 05/29/2019 -- Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one's everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.

Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.

Get PDF of this report template: https://www.qyresearch.com/sample-form/form/1106019/global-ibs-treatment-market

This report studies the IBS Treatment market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of IBS Treatment in these regions, from 2014 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

Allergan Plc (Ireland)

Sucampo Pharmaceuticals (U.S.)

Ironwood Pharmaceuticals, Inc. (U.S.)

Astellas Pharma Inc. (Japan)

Valeant Pharmaceuticals (Canada)

Abbott Laboratories (U.S.)

Synergy Pharmaceuticals, Inc. (U.S.)

Ardelyx, Inc. (U.S.)

Nestle (Switzerland)

Sebela Pharmaceuticals (Ireland)

Probi (Sweden)

Alfasigma USA, Inc. (Italy)

RedHill Biopharma Ltd. (Israel)

AstraZeneca (U.K)

Ipsen (France)

Novartis AG (Switzerland)

Takeda Pharmaceutical Company Ltd (Japan)

Synthetic Biologics, Inc. (U.S.)

Protagonist Therapeutics Inc. (U.S.)

Pfizer Inc (U.S.)

Lexicon Pharmaceuticals, Inc. (U.S.)

Innovate Biopharmaceuticals (U.S.)

By the product type, the market is primarily split into

IBS-D

IBS-C

IBS-M

By the end users/application, this report covers the following segments

Hospitals

Clinics

Research Laboratories

Get Customized Report in your Inbox within 24 hours @: https://www.qyresearch.com/customize-request/form/1106019/global-ibs-treatment-market

Benefits of Purchasing QY Research Report
- Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report
- Customer's Satisfaction: Our expert team will assist with all your research needs and customize the report
- Inimitable Expertise: Analysts will provide deep insights about the reports
- Assured Quality: We focus on the quality and accuracy of the report

About Us: 
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.